Stifel Upgrades Silk Road Medical to Buy, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise has upgraded Silk Road Medical (NASDAQ:SILK) from Hold to Buy and increased the price target from $9 to $20, indicating a positive outlook on the company's stock.
January 19, 2024 | 9:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silk Road Medical has been upgraded by Stifel analyst Rick Wise from Hold to Buy with a significant increase in the price target from $9 to $20.
Upgrades by analysts, especially with a substantial increase in price target, tend to have a positive impact on a stock's price in the short term as they often lead to increased investor confidence and potential buying interest.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100